$NUVB
Nuvation Bio Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023017926 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $7.541M $7.734M $7.463M
YoY Change -15.72% 3.63% 61.89%
% of Gross Profit
Research & Development $18.59M $18.79M $20.73M
YoY Change -35.72% -9.37% 30.54%
% of Gross Profit
Depreciation & Amortization $56.00K $56.00K $46.00K
YoY Change 16.67% 21.74% 53.33%
% of Gross Profit
Operating Expenses $26.13M $26.52M $28.19M
YoY Change -31.0% -5.93% 37.63%
Operating Profit -$26.13M -$26.52M -$28.19M
YoY Change -31.0% -5.93% 37.63%
Interest Expense $5.987M $4.883M $744.0K
YoY Change 3972.79% 556.32% 291.58%
% of Operating Profit
Other Income/Expense, Net $5.491M $4.795M $6.899M
YoY Change 82.3% -30.5% 8313.41%
Pretax Income -$20.64M -$21.73M -$21.29M
YoY Change -40.79% 2.03% 4.37%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$20.64M -$21.73M -$21.29M
YoY Change -40.79% 2.03% 4.37%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09 -$0.10 -$0.10
Diluted Earnings Per Share -$0.09 -$0.10 -$99.77K
COMMON SHARES
Basic Shares Outstanding 218.8M 218.7K 213.4K
Diluted Shares Outstanding 218.8K 218.7K 213.4K

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $630.9M $646.6M $737.7M
YoY Change -10.36% -12.35% -10.55%
Cash & Equivalents $50.07M $30.07M $106.2M
Short-Term Investments $580.8M $616.5M $631.5M
Other Short-Term Assets $3.531M $3.682M $7.841M
YoY Change -54.72% -53.04% 53.75%
Inventory
Prepaid Expenses $7.841M
Receivables
Other Receivables
Total Short-Term Assets $637.2M $652.6M $748.0M
YoY Change -10.79% -12.76% -9.97%
LONG-TERM ASSETS
Property, Plant & Equipment $804.0K $838.0K $747.0K
YoY Change -10.07% 12.18% -3.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $138.0K $138.0K $421.0K
YoY Change 0.0% -67.22% 5.25%
Other Assets
YoY Change
Total Long-Term Assets $4.184M $4.495M $3.768M
YoY Change -23.57% 19.29% 215.84%
TOTAL ASSETS
Total Short-Term Assets $637.2M $652.6M $748.0M
Total Long-Term Assets $4.184M $4.495M $3.768M
Total Assets $641.4M $657.1M $751.8M
YoY Change -10.88% -12.6% -9.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.577M $2.945M $9.673M
YoY Change -79.75% -69.55% 61.14%
Accrued Expenses $9.553M $8.362M $7.121M
YoY Change 25.61% 17.43% 78.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.41M $12.55M $21.44M
YoY Change -36.95% -41.46% 114.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.365M $3.435M $6.801M
YoY Change -37.51% -49.49% -56.68%
Total Long-Term Liabilities $3.365M $3.435M $6.801M
YoY Change -37.51% -49.49% -56.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.41M $12.55M $21.44M
Total Long-Term Liabilities $3.365M $3.435M $6.801M
Total Liabilities $16.78M $15.99M $28.24M
YoY Change -37.06% -43.4% 9.83%
SHAREHOLDERS EQUITY
Retained Earnings -$309.4M -$288.7M -$184.1M
YoY Change 41.28% 56.82% -290.98%
Common Stock $938.4M $932.7M $913.9M
YoY Change 2.11% 2.06% 1.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $624.6M $641.1M $723.6M
YoY Change
Total Liabilities & Shareholders Equity $641.4M $657.1M $751.8M
YoY Change -10.88% -12.6% -9.65%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$20.64M -$21.73M -$21.29M
YoY Change -40.79% 2.03% 4.37%
Depreciation, Depletion And Amortization $56.00K $56.00K $46.00K
YoY Change 16.67% 21.74% 53.33%
Cash From Operating Activities -$17.49M -$19.30M -$24.90M
YoY Change -35.04% -22.49% 69.04%
INVESTING ACTIVITIES
Capital Expenditures $22.00K $12.00K -$7.000K
YoY Change -111.28% -271.43% -93.64%
Acquisitions
YoY Change
Other Investing Activities $37.37M -$51.98M -$5.544M
YoY Change 39.28% 837.66% 471.55%
Cash From Investing Activities $37.35M -$52.00M -$5.551M
YoY Change 40.22% 836.7% 411.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 133.0K 298.0K 4.264M
YoY Change -103.69% -93.01% -99.32%
NET CHANGE
Cash From Operating Activities -17.49M -19.30M -24.90M
Cash From Investing Activities 37.35M -52.00M -5.551M
Cash From Financing Activities 133.0K 298.0K 4.264M
Net Change In Cash 19.99M -71.03M -26.22M
YoY Change -614.51% 170.93% -104.3%
FREE CASH FLOW
Cash From Operating Activities -$17.49M -$19.30M -$24.90M
Capital Expenditures $22.00K $12.00K -$7.000K
Free Cash Flow -$17.51M -$19.31M -$24.89M
YoY Change -34.49% -22.42% 70.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0862255
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
493643000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
122895000
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1500 Broadway
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1401
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
CY2023Q1 dei City Area Code
CityAreaCode
332
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
208-6102
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001811063
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39351
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Nuvation Bio Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
655076000
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
218803722
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30071000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
101099000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3682000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3819000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
616538000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
559915000
CY2023Q1 nuvb Interest Receivable On Marketable Securities Current
InterestReceivableOnMarketableSecuritiesCurrent
2273000
CY2022Q4 nuvb Interest Receivable On Marketable Securities Current
InterestReceivableOnMarketableSecuritiesCurrent
2485000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
652564000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
667318000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
838000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
894000
CY2023Q1 nuvb Lease Security Deposit Noncurrent
LeaseSecurityDepositNoncurrent
138000
CY2022Q4 nuvb Lease Security Deposit Noncurrent
LeaseSecurityDepositNoncurrent
138000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3519000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3791000
CY2023Q1 us-gaap Assets
Assets
657059000
CY2022Q4 us-gaap Assets
Assets
672141000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2945000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2139000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1244000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1206000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8362000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9816000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12551000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13161000
CY2023Q1 nuvb Warrant Liability
WarrantLiability
708000
CY2022Q4 nuvb Warrant Liability
WarrantLiability
850000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2727000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3054000
CY2023Q1 us-gaap Liabilities
Liabilities
15986000
CY2022Q4 us-gaap Liabilities
Liabilities
17065000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
218803722
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
218803722
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
218632699
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
218632699
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
932739000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
927604000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-288728000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-267002000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2938000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5526000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
641073000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
657059000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
314000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3577000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
672141000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18787000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20729000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7734000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7463000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
26521000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
28192000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26521000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-28192000
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
4979000
CY2022Q1 us-gaap Interest Income Other
InterestIncomeOther
958000
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
230000
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
169000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-142000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6324000
CY2023Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-96000
CY2022Q1 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
-214000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4795000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6899000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21726000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21293000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-21726000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21293000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
218741
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
218741
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
213411
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
213411
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-21726000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21293000
CY2023Q1 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
2588000
CY2022Q1 us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
-5032000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19138000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26325000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
655076000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
298000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4837000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-21726000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2588000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
641073000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
745997000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21293000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5032000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
723563000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-21726000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-21293000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4837000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3577000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
56000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
46000
CY2023Q1 nuvb Non Cash Lease Expense
NonCashLeaseExpense
-17000
CY2022Q1 nuvb Non Cash Lease Expense
NonCashLeaseExpense
1000
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-142000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6324000
CY2023Q1 nuvb Net Amortization On Marketable Securities
NetAmortizationOnMarketableSecurities
2147000
CY2022Q1 nuvb Net Amortization On Marketable Securities
NetAmortizationOnMarketableSecurities
-1771000
CY2023Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-96000
CY2022Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-214000
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-12000
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-137000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
4199000
CY2023Q1 us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
-212000
CY2022Q1 us-gaap Increase Decrease In Interest And Dividends Receivable
IncreaseDecreaseInInterestAndDividendsReceivable
-546000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
806000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5748000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1454000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5016000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19330000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24929000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
236967000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
131669000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
184983000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
126125000
CY2023Q1 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
12000
CY2022Q1 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
7000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-51996000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5551000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
298000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
314000
CY2023Q1 nuvb Advance Received From Broker
AdvanceReceivedFromBroker
0
CY2022Q1 nuvb Advance Received From Broker
AdvanceReceivedFromBroker
-3950000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
298000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4264000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-71028000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26216000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
101099000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
132423000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30071000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106207000
CY2023Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5787472
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.50
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
616538000
CY2023Q1 us-gaap Sale Of Stock Description Of Transaction
SaleOfStockDescriptionOfTransaction
the exercise of the Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves more than 50% of the outstanding shares of the Company’s common stock.
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Nature of Operations</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nuvation Bio Inc. and subsidiaries (“Nuvation Bio”), a Delaware corporation, is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio was incorporated on March 20, 2018 (inception date) and has offices in New York and San Francisco.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 10, 2021, (the “Closing Date”), Nuvation Bio Inc., a Delaware corporation (“Legacy Nuvation Bio”), Panacea Acquisition Corp. (“Panacea”), and Panacea Merger Subsidiary Corp, a Delaware corporation and a direct, wholly owned subsidiary of Panacea (“Merger Sub”) consummated the transactions contemplated by an Agreement and Plan of Merger among them dated </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">October 20, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (“Merger Agreement”).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the terms of the Merger Agreement, a business combination of Panacea and Legacy Nuvation Bio was effected through the merger of Merger Sub with and into Legacy Nuvation Bio, with Legacy Nuvation Bio surviving as a wholly owned subsidiary of Panacea (the “Merger”) and, collectively with the other transactions described in the Merger Agreement. On the Closing Date, Legacy Nuvation Bio changed its name to Nuvation Bio Operating Company Inc. and Panacea changed its name to Nuvation Bio Inc. (the “Company” or “Nuvation Bio”).</span></p>
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-288700000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19300000
CY2023Q1 nuvb Cash And Cash Equivalents And Marketable Securities
CashAndCashEquivalentsAndMarketableSecurities
646600000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
209686000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1012000
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
123650000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue and expenses during the year. Accordingly, actual results could differ from those estimates and those differences could be significant. Significant estimates and assumptions reflected in the accompanying consolidated financial statements include, but are not limited to, warrant liabilities, leases, stock options granted and depreciation expense.</span>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of government and corporate bonds, municipal securities and exchange traded fund with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.</span></p>
CY2023Q1 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
2366000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
333336000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
3378000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
253605000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1650000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
212814000
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
27666000
CY2023Q1 us-gaap Marketable Securities
MarketableSecurities
616538000
CY2023Q1 nuvb Total Financial Assets
TotalFinancialAssets
644204000
CY2023Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
708000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
68311000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
559915000
CY2022Q4 nuvb Total Financial Assets
TotalFinancialAssets
628226000
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
850000
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
647142000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
440000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3378000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
644204000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
633752000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
86000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5612000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
628226000
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2022Q1 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
7000
CY2023Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
96000
CY2022Q1 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
50000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-96000
CY2022Q1 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-43000
CY2023Q1 us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
0
CY2022Q1 us-gaap Equity Securities Fv Ni Unrealized Loss
EquitySecuritiesFvNiUnrealizedLoss
337000
CY2023Q1 us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
0
CY2022Q1 us-gaap Equity Securities Fv Ni Realized Gain
EquitySecuritiesFvNiRealizedGain
166000
CY2023Q1 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
0
CY2022Q1 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-171000
CY2023Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-96000
CY2022Q1 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-214000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
3962000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
466419000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
5612000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1072000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1495000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1071000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
631000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
81000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4350000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
379000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
3971000
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M9D
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5526000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1185000
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
2492000
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-5075000
CY2023Q1 nuvb Realized Loss On Marketable Securities
RealizedLossOnMarketableSecurities
96000
CY2022Q1 nuvb Realized Loss On Marketable Securities
RealizedLossOnMarketableSecurities
43000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2938000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6217000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4837000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3577000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.05
CY2023Q1 us-gaap Market Risk Benefit Change In Fair Value Gain Loss
MarketRiskBenefitChangeInFairValueGainLoss
100000
CY2023Q1 nuvb Fair Value Equity Level1 To Level2 Or Level3 Transfers Description
FairValueEquityLevel1ToLevel2OrLevel3TransfersDescription
no
CY2023Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
708000
CY2022Q4 nuvb Changes In Liabilities Classified In Level3 Of Fair Value Hierarchy
ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy
37000
CY2023Q1 nuvb Change In Fair Value Of Private Warrants Liability Recognized In Earnings
ChangeInFairValueOfPrivateWarrantsLiabilityRecognizedInEarnings
-4000
CY2023Q1 nuvb Changes In Liabilities Classified In Level3 Of Fair Value Hierarchy
ChangesInLiabilitiesClassifiedInLevel3OfFairValueHierarchy
33000

Files In Submission

Name View Source Status
0000950170-23-017926-index-headers.html Edgar Link pending
0000950170-23-017926-index.html Edgar Link pending
0000950170-23-017926.txt Edgar Link pending
0000950170-23-017926-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nuvb-20230331.htm Edgar Link pending
nuvb-20230331.xsd Edgar Link pending
nuvb-ex10_1.htm Edgar Link pending
nuvb-ex31_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nuvb-20230331_cal.xml Edgar Link unprocessable
nuvb-20230331_def.xml Edgar Link unprocessable
nuvb-20230331_lab.xml Edgar Link unprocessable
nuvb-20230331_pre.xml Edgar Link unprocessable
nuvb-20230331_htm.xml Edgar Link completed
nuvb-ex31_2.htm Edgar Link pending
nuvb-ex32_1.htm Edgar Link pending
nuvb-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending